通道阻塞剂增加了大动脉动脉瘤和剖析风险
Tianfeng Ma1, Zeyu Cai2, Xinming Xu3
1Department of Vascular and Endovascular Surgery, Chinese PLA General Hospital, Beijing, China.
Nature communications
|December 24, 2025
概括
通道阻塞剂 (CCBs) 可能会增加大动脉动脉瘤和剖析 (AAD) 的风险. 此外,CCB还在小鼠模型和患者中恶化了AAD结果,这表明在为高血压开处方时要谨慎.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 血管生物学 血管生物学
背景情况:
- 大动脉动脉瘤和剖析 (AAD) 是一种严重的血管疾病,缺乏有效的药理疗法.
- 血管光滑肌细胞 (VSMC) 收缩能力受损与AAD病变发生有关.
- 通道阻断剂 (CCB) 在AAD发育和进展中的确切作用尚不清楚.
研究的目的:
- 调查使用通道阻塞剂 (CCB) 与大动脉动脉瘤和剖析 (AAD) 风险之间的关联.
- 评估CCB对临床前模型和人类患者AAD进展和结果的影响.
主要方法:
- 分析了英国生物库501,878名参与者的数据,平均随访时间为13.5年.
- 在小鼠模型中评估CCB对大动脉硬性和AAD发育的影响.
- 评估CCB对AAD回归对B型大动脉切割后内血管修复患者的影响.
主要成果:
- 与未经治疗的高血压患者相比,CCB使用者表现出明显更高的AAD风险 (危险比率=1.31).
- 在小鼠模型中,CCBs加剧了大动脉硬度,并促进了AAD的发展.
- 在接受B型大动脉剖析内血管修复的患者中,CCB的使用与有限的AAD回归有关.
- 抑制cGMP依赖的蛋白质激酶1 (PRKG1) 减弱了CCB诱导的AD进展.
结论:
- 通道阻塞剂 (CCB) 可能与大动脉动脉瘤和剖析 (AAD) 的风险增加有关.
- CCBs可能会对AAD预后和术后结果产生负面影响.
- 建议在给高血压患有AAD风险的高血压患者开药时谨慎使用CCB.
相关概念视频
Antihypertensive Drugs: Action of Calcium Channel Blockers
1.5K
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.5K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.5K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.2K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.2K
Antiepileptic Drugs: Calcium Channel Blockers
1.1K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.1K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.7K
Aneurysm II: Clinical Manifestations and Diagnostic Studies
193
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
193


